Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMvigor130 phase III trial of atezolizumab alone or with platinum-based chemotherapy in untreated advanced urothelial carcinoma
MOH_2017-06-05_000260Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of atezolizumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Roche. Primary endpoints: Efficacy of atezolizumab plus platinum-based chemotherapy versus placebo plus platinum-based chemotherapy and Overall survival with atezolizumab monotherapy versus placebo plus platinum-based chemotherapy. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2017-06-05_000260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-05_000260.